THERAPY FOR CHAGAS DISEASE IN BABOON MODEL

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 恰加斯病是由一种寄生虫引起的，这种寄生虫由一种吸血虫携带，在中美洲和南美洲以及美国南部流行。这种疾病会引起免疫系统的紊乱，并导致心脏病理学。 感染的灵长类动物不应用于传染病研究或心脏研究。 在SNPRC，2%的狒狒、4%的恒河猴和12%的黑猩猩被感染。 我们知道，这种感染也是地方性的，至少在美国南部的其他一些灵长类动物设施中，查加斯病没有治疗方法。 动物或人类的初始感染持续终身。 然而，泊沙康唑，一种被批准为人类使用的抗真菌新药，在治疗实验性感染寄生虫的小鼠时，在消除寄生虫方面表现出高水平的功效。 我们正在一项研究中测试这种药物在消除寄生虫方面的有效性，该研究涉及自然感染的狒狒。 该实验将在研究开始和结束时进行肌内膜活检，以便确定心脏中的寄生虫水平和病理进展。 如果治疗成功，我们预计它在美国南部灵长类动物设施的使用将降低青少年和饲养者的发病率和死亡率，并将增加可用于传染病研究的动物数量。 即使治疗只是部分成功，受感染动物的健康状况也可能得到改善。 此外，如果实验至少取得部分成功，结果将证明非人灵长类动物作为开发恰加斯病治疗方法的模型的实用性，该疾病影响拉丁美洲的1000万人，估计美国有10万人。以及美国南部数量不明的非人类灵长类动物。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. Chagas disease is caused by a parasite that is carried by a blood-sucking bug that is endemic in Central and South America and in southern U.S. This disease causes perturbations in the immune system and it causes cardiac pathology. Infected primates should not be used for studies in infectious disease research or cardiac research. At the SNPRC 2% of baboons, 4% of rhesus macaques and 12% of chimpanzees are infected. We know that this infection also is endemic at at least some of the other primate facilities in the southern U.S. There is no treatment for Chagas disease. The initial infection in animals or humans persists lifelong. However, posaconazole, a new drug that is approved as an anti-fungal for human use, has demonstrated a high level of efficacy in eliminating the parasites in treatment of mice that were experimentally infected with the parasite. We are testing this drug in a study involving naturally infected baboons for its efficacy in eliminating the parasite. The experiment will involve endomyocardial biopsy at the beginning and at the end of the study so that parasite levels in the heart and pathological progression can be determined. If the treatment is successful, we expect that its use at primate facilities in southern U.S. will decrease morbidity and mortality among juveniles and breeders, and will increase the number of animals available for research on infectious diseases. Even if the treatment is only partially successful, the health status of infected animals may improve. Furthermore, if the experiment achieves at least partial success, the results will demonstrate the utility of nonhuman primates as models for developing treatments for Chagas disease, which affects 10 million people in Latin America and an estimated 100,000 people in the U.S., as well as an undetermined number of nonhuman primates in the southern U.S.